Efficacy and safety findings from MANTRA: A global, randomized, multicenter, phase III study of the MDM2 inhibitor milademetan vs trabectedin in patients with dedifferentiated liposarcomas

T. W-W. Chen, R. Sanfilippo,R. L. Jones, S. M. Schuetze,A. Sebio Garcia,R. M. Alvarez, N. Bui, J-H. Ahn, H. H. F. Loong,C-C. Yen, J. Y. Hong,H. S. Kim, S. Patel, R. P. Bryce, F. Xu, B. Zhang, N. V. Shah, R. C. Doebele, G. Schwartz, M. Gounder

ANNALS OF ONCOLOGY(2023)

引用 1|浏览0
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要